U.S. Aorto-iliac Occlusive Disease Treatment Market Global Insights And Revenue Growth Up To 2030

U.S. Aorto-iliac Occlusive Disease Treatment Market Summary

The U.S. aorto-iliac occlusive disease (iliac disease) treatment market was valued at USD 716.6 million in 2024 and is anticipated to expand at a compound annual growth rate (CAGR) of 5.4% from 2025 to 2030. The market is primarily driven by the increasing prevalence of peripheral artery disease (PAD), growing governmental support, and continued technological innovation. For instance, in November 2024, Philips launched the THOR IDE clinical trial in the U.S. to assess a new hybrid catheter system that combines laser atherectomy with intravascular lithotripsy. This next-generation device aims to address heavily calcified lesions, which are frequently present in PAD and aorto-iliac disease.

The system is engineered to simplify complex vascular interventions and improve patient outcomes by reducing procedural time and increasing precision. The first successful clinical use of this device took place at the Cardiovascular Institute of the South in Louisiana, marking a milestone in advancing endovascular therapy. Governmental efforts are also boosting the market. A notable initiative includes the Arterial and Venous Comprehensive (ARC) Act, introduced in June 2023 as per a Congress.Gov article. This act seeks to amend the Social Security Act, enabling Medicare and Medicaid beneficiaries who are considered high-risk to access PAD screenings without financial burden, thereby promoting early diagnosis and timely treatment.

Key Market Trends & Insights

• In 2024, the endovascular devices segment dominated the market, accounting for a substantial 87.8% share. These devices are critical in re-establishing blood flow in patients suffering from aorto-iliac and peripheral arterial disease. Their adaptability and compatibility with a range of vascular procedures make them a preferred choice among medical professionals.
• Hospitals accounted for the largest share of 49.2% in 2024 within the healthcare facility segment. These institutions are equipped with comprehensive diagnostic and interventional infrastructure, as well as specialized vascular teams, enabling them to offer holistic care for patients with complex arterial conditions.
• Moreover, in 2024, the endovascular procedure segment led the market with a 61.1% share. The growing preference for minimally invasive techniques has made endovascular procedures a standard in aorto-iliac occlusive disease treatment. These methods are associated with lower complication rates, reduced hospitalization time, and faster patient recovery, making them highly favorable.

Order a free sample PDF of the U.S. Aorto-iliac Occlusive Disease Treatment Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 716.6 million
• 2030 Projected Market Size: USD 978.6 million
• CAGR (2025 - 2030): 5.4%

Key Companies & Market Share Insights

Some key established players operating in the market include Abbott, Boston Scientific Corporation, Medtronic, W. L. Gore & Associates, Inc., Terumo Corporation, and Cook. These companies are collaborating with regional players to expand their services geographically. iVascular, Limflow, and Vesper Medical are some emerging market participants. Emerging players focus more on collaborating with various research institutions to improve their clinical reach across the healthcare ecosystem.

Key Players

• BD
• Abbott
• Boston Scientific Corporation
• W. L. Gore & Associates, Inc.
• Medtronic
• Cook
• Terumo Corporation
• Getinge AB

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The U.S. aorto-iliac occlusive disease treatment market is poised for steady growth, driven by rising PAD cases, supportive legislation, and cutting-edge device innovations. As healthcare systems increasingly emphasize early detection and non-invasive treatment, the adoption of advanced endovascular technologies will continue to surge. Legislative initiatives such as the ARC Act further reinforce this shift by making screening more accessible to high-risk populations. With hospitals and specialized vascular centers adopting newer technologies, patient outcomes are expected to improve significantly. Overall, the synergy between public health policy and technological innovation is set to transform the treatment landscape for aorto-iliac occlusive disease in the coming years.